News BMS adds to IBD pipeline with $1.9bn GentiBio deal Bristol-Myers Squibb has formed an R&D partnership with GentiBio, aimed at developing regulatory T cel (Treg) therapies for inflammatory bowel disease (IBD).
News FDA clears AZ's Imfinzi for aggressive lung cancer AstraZeneca's Imfinzi becomes the first cancer immunotherapy to be FDA-approved for limited-stage small cell lung cancer (LS-SCLC).
Digital Sponsored The AI effect in pharma commercial strategy: From data to re... Discover how AI is transforming the pharma commercial strategy. Unlock real-time insights & actions from data. Click here for more.